A TH9507 and ipamorelin blend combines two compounds that engage growth hormone release through entirely separate receptors. What is TH9507 covers the compound's background as a stabilized GHRH(1-44) analog on its own; this article looks specifically at why it gets paired with ipamorelin, what each contributes based on its own published literature, and how researchers approach the concentration math when two peptides share a single vial.
| Attribute | Detail |
|---|---|
| TH9507 | A stabilized analog of growth hormone-releasing hormone (GHRH 1-44), engaging the GHRH receptor on pituitary somatotrophs |
| Ipamorelin | A selective agonist at the ghrelin receptor (GHS-R), studied as a growth hormone secretagogue |
| Rationale for pairing | Two independent receptor pathways feeding into the same pulsatile growth hormone release system |
| What TH9507's own literature measured | Visceral fat, IGF-I levels, and inflammatory markers in randomized controlled trials in an HIV-associated lipodystrophy population |
| What ipamorelin's own literature measured | Growth hormone release and hormone selectivity in early rodent and pig pharmacology studies |
| Form supplied | Lyophilized powder, research use only |
Where does TH9507 come from mechanistically?
TH9507 is built on the backbone of native growth hormone-releasing hormone, the hypothalamic peptide first characterized from a human pancreatic islet tumor in the early 1980s (Rivier et al., 1982). That original characterization established GHRH as a direct pituitary-acting releasing factor, and TH9507 was developed as a stabilized version of the same 1-44 amino acid sequence with modifications intended to resist enzymatic degradation and extend its usable half-life relative to the native hormone. This stabilization is the reason TH9507, rather than unmodified GHRH, is the GHRH-pathway compound most often used in controlled research settings today.
What does TH9507's own clinical literature report?
TH9507 has one of the more extensive human trial records of any compound in this category, largely from research in HIV-associated lipodystrophy. A pooled analysis of two multicenter, placebo-controlled phase 3 trials reported reductions in visceral adipose tissue and changes in IGF-I levels in TH9507-treated participants relative to placebo, with safety extension data collected over an additional treatment period (Falutz et al., 2010). A related analysis from the same trial population reported that the visceral fat reduction observed with TH9507 was associated with favorable shifts in lipid and glucose-handling markers, treating the metabolic profile change as a secondary outcome linked to the primary visceral fat measurement (Stanley et al., 2012). A separate report from the same research group examined inflammatory marker levels in the same patient population and found a relationship between the degree of visceral adipose reduction and changes in specific inflammatory markers, suggesting the metabolic and inflammatory findings were connected to the same underlying fat-mass change rather than independent drug effects (Stanley et al., 2011).
What does ipamorelin's own pharmacology literature report?
Ipamorelin's foundational characterization work is pharmacological rather than clinical: the compound was tested in rodent and pig models and reported to stimulate growth hormone release through the ghrelin receptor while producing comparatively little change in cortisol or prolactin, a selectivity profile the original authors used to distinguish it from earlier, less selective ghrelin-receptor agonists (Raun et al., 1998). Because ipamorelin's literature is concentrated in this early pharmacological characterization rather than in large human outcome trials of the kind that exist for TH9507, researchers pairing the two compounds are generally combining a well-characterized human clinical dataset on one side with a well-characterized receptor-pharmacology dataset on the other, rather than two datasets measured on the same scale.
What is the rationale for blending the two rather than testing each alone?
The pairing rationale rests on receptor non-overlap rather than on a large body of combined-administration human trials specifically testing TH9507 with ipamorelin together. Because TH9507 acts on the GHRH receptor and ipamorelin acts on the separate ghrelin receptor, researchers modeling combined administration are testing whether engaging both arms of the pulsatile growth hormone release system produces a different response curve than either compound alone, using each compound's individually established mechanism as the basis for the comparison. As with the CJC-1295 and ipamorelin pairing described in growth hormone secretagogues explained, direct combined-dosing trial data specific to this exact pairing is limited relative to the volume of research on each half separately.
How is the blend concentration worked out?
A blend vial contains two peptides at defined amounts dissolved into a single reconstitution volume, and because TH9507 and ipamorelin have different molecular weights, converting a combined vial's total content into a working concentration for each peptide requires tracking the two amounts separately rather than treating the vial as a single substance. The general math for this, including how to handle two peptides with different molecular weights sharing one solvent volume, is covered step by step in calculating peptide blend concentrations.
This distinction matters more for a blend than for a single-peptide vial because the two components are not interchangeable on a milligram-for-milligram basis. A given mass of TH9507 represents a different number of moles than the same mass of ipamorelin, since the two peptides differ in molecular weight, so a researcher tracking receptor engagement per mole of active compound needs the underlying concentration math rather than just the combined label weight. Keeping a written record of how each vial's combined content was converted into individual working concentrations also makes it easier to compare results across batches or across a series of experiments that draw from more than one lot.
Handling notes
TH9507 and ipamorelin blends are supplied as lyophilized powder for laboratory research. Store per the certificate of analysis and confirm identity and purity against the lot-specific documentation before use in an assay. Lot-specific specs for this blend are posted on our TH9507 and ipamorelin lot page.
Frequently asked questions
Do TH9507 and ipamorelin act on the same receptor?
No. TH9507 engages the GHRH receptor as a stabilized GHRH(1-44) analog, while ipamorelin engages the separate ghrelin receptor (GHS-R). The two mechanisms are studied as complementary rather than redundant.
Which of the two compounds has more human trial data?
TH9507 has a substantially larger human clinical trial record, largely from research in HIV-associated lipodystrophy. Ipamorelin's literature is concentrated in earlier rodent and pig pharmacology characterization work.
Has the TH9507-ipamorelin combination itself been tested directly?
Direct combined-administration trial data specific to this exact pairing is limited in the published literature. The rationale for combining them is built from each compound's separately established receptor mechanism.
Why does the blend use two different molecules instead of a higher amount of one?
Because TH9507 and ipamorelin act on two distinct, non-overlapping receptor pathways feeding into the same pulsatile release system, researchers study the pairing as a way to test whether engaging both pathways produces a different response than scaling up either compound alone.
Is this blend research done in humans?
The TH9507 trials cited here were conducted in human clinical populations. The ipamorelin pharmacology cited here was conducted in animal models. This article summarizes published research and is not guidance for use in any subject.
References
- Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276-8. PubMed 6292724.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of TH9507 (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713.
- Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving TH9507. Clin Infect Dis. 2012;54(11):1642-51. PubMed 22495074.
- Stanley TL, Falutz J, Grinspoon SK, et al. Effects of TH9507 on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-8. PubMed 21516030.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.
